Hey Roka - can you elaborate on your statement above:
"Not that they are trying to hide anything, it's just that the PTSD trial isn't large enough and run long enough to show an affect on everything, and it's not necessary for PTSD specifically."
I am not sure I follow your logic?
If this trial is not going to be a significant confirmation of BNC 210 effectiveness in PTSD, why all the fuss????
Surely ts big enough to give some pretty useful info.
I assume that if it does, then there will be strong incentive to press ahead and not license.
If sale proceeds from oncology asset sales are larger than originally expected by me and others, then we may not be as close to licensing deal on BNC 210 as we originally thought...........
It would be nice if the company shared their thinking - even if its preliminary - and even if they change their mind........
Poor communications is a hallmark I am afraid..........
What am I missing here?????
BNO Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held